News Briefing channel feed

News brief­ing: HHS chas­tis­es Eli Lil­ly for end­ing some dis­counts in a pan­dem­ic; Gilead to pay $97 mil­lion to set­tle kick­back al­le­ga­tions

5 years ago

News brief­ing: PureTech plans Nas­daq de­but with sec­ondary list­ing; GoodRx prices $725M IPO

5 years ago

News brief­ing: Tiny Vac­cinex's drug flops in PhII Hunt­ing­ton's tri­al, stock craters; Siol­ta nabs $30M Se­ries B to de­vel­op mi­cro­bio­me drug

5 years ago

News brief­ing: Bausch Health clos­ing in on deal to ac­quire Al­le­gro as­sets; PharmAbcine strikes deal with Sam­sung Bi­o­log­ics to de­vel­op an­ti­body pro­gram

5 years ago

News brief­ing: Com­pa­ny de­vel­op­ing 'mag­ic mush­room' treat­ment hits Nas­daq; Spring­Works en­ters spon­sored re­search agree­ment with Fred Hutch

5 years ago

News brief­ing: Check­point reads out new in­ter­im mC­SCC da­ta; Taysha eyes $125M for its flash IPO

5 years ago

News brief­ing: Top FDA of­fi­cial ex­its; Sun Ge­nomics clos­es $9.25M Se­ries A

5 years ago

News brief­ing: Fre­quen­cy posts ex­tend­ed pos­i­tive re­sults for hear­ing loss pro­gram; Kiniksa earns ODD for GCA can­di­date

5 years ago

News brief­ing: No­var­tis eyes ex­pan­sion for Eylea ri­val with PhI­II re­sults; Dupix­ent ob­tains BTD for EoE

5 years ago

News brief­ing: Roche shows off more MS, NMOSD da­ta; Gala­pa­gos and Gilead clear PhI­Ia pri­ma­ry end­points but re­port SAEs

5 years ago

News brief­ing: Take­da re­ports PhI­II fail­ure for Nin­laro in mul­ti­ple myelo­ma; As­traZeneca plots piv­ot to Nas­daq

5 years ago

News brief­ing: Catal­ent, Mer­ck KGaA make big in­vest­ments in man­u­fac­tur­ing ops; J&J teams with Data­vant on da­ta shar­ing projects

5 years ago

News brief­ing: Ex­elix­is rolls the dice with 2 ADC deals tied to $35M cash up­fronts; A rare an­tibi­ot­ic win for promi­nent­ly-backed Spero

5 years ago

News brief­ing: Kite looks to ex­pand Yescar­ta fran­chise with new in­di­ca­tions; Tiny Lixte looks to up­list on Nas­daq

5 years ago

News brief­ing: Io­n­is reads out pos­i­tive da­ta for prekallikrein-tar­get­ing drug; PPD col­lab­o­rates on lu­pus re­search

5 years ago

News brief­ing: Amar­in's pan­el could put Vas­cepa patents in jeop­ardy; San­thera nabs a Duchenne drug

5 years ago

News brief­ing: No­var­tis hands off NASH drug to biotech col­lab­o­ra­tor, al­so plans to build new Basel pro­duc­tion unit

5 years ago

Gene ther­a­py up­start re­cruits more ex-AveX­is tal­ent; I-Mab re­veals first-half re­sults

5 years ago

Fortress Biotech takes out $60M loan for debt pur­pos­es; En­ta­sis pulls in $25M pri­vate place­ment for PhI­II tri­al

5 years ago

A nano-cap strug­gles to ride the IPO wave; Seat­tle Ge­net­ics gets a GSK mile­stone

5 years ago

Tizona com­pletes spin­out of can­cer pro­gram as part of Gilead buy­out; Dyne files for $100M IPO

5 years ago

ATAI adds MD­MA biotech to grow­ing list of psy­che­del­ic mak­ers; Aca­dia adds $52.5M up­front pain buy­out

5 years ago

Odonate an­nounces 'pos­i­tive' re­sults but faces in­vestor back­lash; Aslan is once again re­cruit­ing clin­i­cal tri­al par­tic­i­pants af­ter months-long wait amid the pan­dem­ic

5 years ago

Bio­Marin sub­mits NDA for con­tro­ver­sial achon­dropla­sia drug; Cell and gene ther­a­py boom sparks €49M buy­out

5 years ago
First page Previous page 37383940414243 Next page Last page
A service from the Financial Times